Rheumatoid Arthritis/Osteoarthritis Sarah Daoud Florida A&M University College of Pharmacy and...
-
Upload
quentin-grigsby -
Category
Documents
-
view
216 -
download
3
Transcript of Rheumatoid Arthritis/Osteoarthritis Sarah Daoud Florida A&M University College of Pharmacy and...
Rheumatoid Arthritis/Osteoarthritis
Sarah DaoudFlorida A&M University College of Pharmacy and Pharmaceutical Sciences10/02/13Seminar: Disease Presentation
Objectives
Discuss the prevalence, epidemiology, risk factors, and pathophysiology of RA/OA.
Discuss the signs and symptoms, diagnosis, and treatment of RA/OA.
Assess treatment of disease states in special populations.
Evaluate the role of the pharmacist in the overall approach of these conditions.
Discuss key components of RA/OA which would serve as educational points for patients and healthcare practitioners.
RHEUMATOID ARTHRITIS
Prevalence
RA is the most common form of autoimmune arthritis affecting more than 1.3 million Americans.
Women encompass 75% of individuals diagnosed with this disease.
1-3% of women may get RA in their lifetime.
Usual occurrence is in individuals between 40-60 years of age.
Epidemiology
RA does not have any racial inclination and can occur at any age.
Research has shown, this disease has a genetic predisposition and diagnosis may be necessitated by certain unknown environmental exposures.
Major histocompatibility complex (MHC) molecules located on T-lymphocytes play a major role in patients with RA.
Human lymphocyte antigen (HLA) typing can characterize these molecules and assess the risk of RA in those with presence of antigens on MHC molecules.
Risk Factors
Sex (Female)
Family history
Older age
Silicate exposure
Smoking
Consuming 3 or more cups of coffee/day (esp. decaffeinated coffee)
Pathophysiology
Signs and Symptoms
Morning stiffness lasting hours (sometimes whole day)
Fatigue
Weakness
Low-grade fever
Loss of appetite
Joint pain
Firm lumps
***Joint involvement tends to be symmetrical
Diagnosis
Non-pharmacological Treatment
Rest
Occupational therapy
Physical therapy
Use of assistive devices
Weight reduction
Surgery
Pharmacological Treatment
Pharmacological Treatment Agents used for pain and inflammation
Drug Dosage Adverse Effects
Warnings/Contraindications
Notes
Ibuprofen (Motrin, Advil)
->200-400mg Q6-8H (mild to moderate pain)->600-800mg Q6-8H; max 3.2g/d (moderate pain or inflammation)
-Dyspepsia-Heartburn-Increase BP-GI bleeding
-NSAIDS have BBW of increased risk of adverse CV thrombotic events; contraindicated for CABG perioperative pain; increased GI adverse events (ulceration, bleeding, perforation)-Contraindicated in pregnancy 3rd trimester.
-Avoid use in advanced renal disease.
Celecoxib (Celebrex) ->100-200mg BID -Diarrhea-Nausea
-Warnings are the same as NSAIDS.-Contraindicated with sulfa allergy.
-Lower risk of GI complications.-Max 400mg
Prednisone (Rayos, Prednisone Intenson)
->Initial 5-60mg daily indicated for acute inflammation->Can use twice daily dose every other day to decrease adrenal suppression.
-Fluid retention-Stomach upset-Increase appetite.-Hyperglycemia-Osteoporosis-Muscle wasting
-Contraindicated with live vaccines, systemic lung infections.
-Must assess bone density if used long-term.-Must taper dose off.
Pharmacological Treatment Non-biologic Disease-modifying anti-rheumatic drugs (DMARDS)Drug Dosage Adverse Effects Warnings/
ContraindicationsNotes
Methotrexate (Rheumatrex, Trexall)
-folate antimetaboline that inhibits DNA synthesis
->7.5-22.5mg/week
-N&V-Diarrhea-GI upset-Anorexia-Reddening of skin
-BBW: fetal death or congenital abn.; hepatotoxicity; BMS; malignant lymphomas; acute renal failure.-Contraindications: pregnancy; alcoholism; chronic liver disease; blood dyscrasias
-Never dose daily for RA (dose can be split into smaller doses taken over 12-36 hours)-Pregnancy category X
Hydroxychloroquine (Plaquenil)
->Initial: 400-600mg/day->Maintain: 200-400mg/day
-Decreased visual acuity-Photophobia-Blurred vision-Corneal deposits
-Can cause neuromyopathy with long-term use; SJS; alopecia; pigmentation of skin and hair (bleaching)
-Used in mild RA-Take with food or milk-Mainly eliminated by the kidney
Sulfasalazine (Azulfidine, Sulfazine)
-5-aminosalicyclic acid derivative
->500-1,000mg BID; max 3g/day
-Headache-Anorexia-Dyspepsia-GI upset
-Contraindications: pts with a sulfa or salicylate allergy, GI or GU obstruction-Can cause reversible oligospermia; folate deficiency d/t impaired folate absorption
-Take with food and 8oz of water to prevent crytalluria-Can cause yellow-orange discoloration of skin/urine-May give 1mg/day folate supplement
Pharmacological Treatment Non-biologic DMARDS cont.
Drug Dosage Adverse Effects
Warnings/Contraindications Notes
Minocycline (Dynacin, Minocin, Solodyn)
->100mg BID
-GI upset-N&V
-May cause SJS and decreased LFTs
-Used in mild RA-Pregnancy Cat. D-Do not use in children 8 yoa or younger.
Leflunomide (Arava)
-> 100mg x3days, then 20mg daily
-Diarrhea-URTIs-Rash-Alopecia
-BBW: women of childbearing potential should not use age until pregnancy is excluded; hepatotoxicity
-Must have negative pregnancy test before starting and use 2 forms of birth control.-If pregnancy wanted, must wait 2 yrs after discontinuation or give cholestyramine.-Can use with or without methotrexate-Pregnancy Cat. X
Pharmacological Treatment Biologic agents- TNFalpha inhibitors
BBW: serious infxs; lymphomas; malignancies; perform test for latent TB before initial therapy.
Contraindication: sepsis Can cause worsening or new onset Heart Failure; hep. B
reactivation; demyelinating disease. Do not give with other biologics or live vaccines SE: infections and injection site reactions Administration: do not shake; require refrigeration; allow to
reach room temp. before injecting These agents are usually add-on therapy to methotrexate
Pharmacological Treatment Biologic DMARD agents- TNFalpha inhibitors
Drug Dosage Notes
Etanercept (Enbrel) ->50mg SC once/week
Adalimumab (Humira) ->40mg SC every other week -If not taking MTX, can increase dose to 40mg SC weekly
Infliximab (Remicade) ->3mg/kg IV at weeks 0,2,6 and then Q8W can increase to 10mg/kg
-Higher dose=increase infx risk-Infusion reaction: hypotension, fever, chills, pruritis (benefit from APAP/ antihistamine/ steroids as pre-treatment)-Delayed hypersensitivity rxn 3-10d after admin (fever, rash, myalgia, HA, sore throat)
Certolizumab pegol (Cimzia) ->400mg SC at weeks 0,2,4 and then 400mg Q4W
-Can maintain at 200mg every other week
Golimumab (Simponi) ->50mg SC once/month -Give with MTX
Pharmacological Treatment Biologic response modifiers
Drug Dosage Adverse Effects
Warnings/Contraindications
Notes
Rituximab (Rituxan)-depletes CD20+ B cells
->1g IV day 1 and 15 @50mg/hr (can increase to 400mg/hr if no rxn)
-Fever-Chills-Angioedema-BMS-Abdominal pain
-BBW: severe and fatal infusion related reactions; PML due to JC virus infection; tumor lysis syndrome leading to acute renal failure and dialysis; SJS, TEN can occur-Warnings: serious infxs
-Pre-medicate with a steroid-Used with MTX-Do not give with live vaccines or other biologics-Screen for latent TB before initiating
Anakinra (Kineret)-IL-1 receptor antagonist
->100mg SC daily -Headache-Infections-BMS-Injection site rxn
-Warnings: serious infxs -Do not give with live vaccines or other biologics-Screen for latent TB before initiating
Abatacept (Orencia)-Selective T cell costimulation blocker
->500mg-1,000mg IV based on body wt; given over 30min
-Headache-Infections-Injection site rxn
-Warnings: serious infxs -Do not give with live vaccines or other biologics-Screen for latent TB before initiating
Pharmacological Treatment
Drug Dosage Adverse Effects
Warnings/ Contraindications Notes
Tofacitinib (Xeljanz)
-inhibitor of Janus kinase (JAKs)
->5mg PO BID
-URTIs-Diarrhea-Headache
-BBW: can cause serious infections, lymphomas and other malignancies; screen for latent TB-Can cause GI perforation-Not recommended in severe hepatic impairment-Do not give with live vaccines
-Do not use with potent 450 inducers; reduce dose to 5mg daily w/ potent 3A4 and 2C19 inhibitor.-Do not use with biological DMARDs or potent immunosuppressants-Monitor neutrophil count, hemoglobin, and lymphocyte count
Kinase Inhibitors
OSTEOARTHRITIS (AKA: Degenerative Joint Disease)
Prevalence
An estimated 15.8 million adults display symptoms of OA
Prevalence increased with age E.g. Those aged 75-79 years, 85% have OA of the hands,
whereas those 45 year and younger, only 1/5th have OA of the hands.
Severity also increases with age
Women are more affected
Knee OA twice as prevalent in black opposed to white women
Epidemiology
Most prevalent of the rheumatic diseases
Responsible for disability and loss of productivity
OA at some skeletal sites occurs in nearly everyone 75 years and older
½ million symptomatic cases of idiopathic OA occur yearly in the US white population
Risk Factors
Obesity
Repetitive motion (constant stress on hand, knee, etc.)
Joint injury
Genetics
Type and intensity of physical activity
Pathophysiology
Signs and Symptoms
Pain with motion
Joint stiffness lasting <30min (usually in the morning)
Joint: Tenderness Crepitus Enlargement
Diagnosis
3 Goals: Differentiate between
primary or secondary OA
Clarify joints involved Assess prior therapies
Diagnostic Parameters: OA of knee-
Refer to signs and symptoms
Age >50yo OA of hand-
Heberden’s node (2 or more out of 10)
OA of hip- Normal ESR Osteophytes and joint
space narrowing on on X-ray
Non-pharmacological Treatment
Exercise programs (aquatic)
Weight loss
Patient education for self-management
Wedged shoe insoles
Rest
Braces (symptomatic relief)
Pharmacological Treatment Pain Relief (primary indication for pharmacological treatment)
Drug Dosage Adverse Effects
Warnings/ Contraindications
Notes
Acetaminophen (Tylenol)
->650-1000mg PO Q6H
-Constipation-Headache-Vomiting
-Contraindications; hepatic impairment-Alcoholism can increase hepatic injury
-For mild to moderate pain-Max 4g/day
Tramadol (Ultram) ->initial: 25mg/day, increase by 25mg increments in separate doses every 3 days->maintain: 50-100mg PO Q4-6H
-Flushing-Constipation-Headache-Nausea-Xerostomia
-Contraindications: hypercapnia, severe bronchial asthma, acute intoxication with alcohol, narcotics, etc.
-For moderate to severe pain-Max 400mg/day-Adjust dose for renal impairment
Pharmacological TreatmentOpioid Analgesics
Drug Dosage Adverse Effects
Warnings/ Contraindications
Notes
Codeine sulfate ->15-60mg PO Q4H
-Somnolence-Dyspnea-Hypotension-Bowel obstruction-Pancreatitis
-Contraindications: bronchial asthma, hypercarbia-Has potential for abuse-May cause diminished biliary and pancreatic secretions-May prolong GI obstruction
-For mild to moderate pain-Max dose: 360mg/day
Oxycodone hydrochloride
->5-15mg PO Q4-6H
-Constipation-Nausea-Somnolence
-BBW: fatal respiratory depression-Contraindications: bronchial asthma, hypercarbia
-For moderate to severe pain
Pharmacological TreatmentNSAIDSDrug Dosage Adverse
EffectsWarnings/ Contraindications Notes
Aspirin ->Up to 3g/day in divided doses
-GI upset-Bleeding-GI ulcer
-Caution with bleeding disorders, renal or hepatic disease
-May take with food or milk
Ibuprofen(Advil)
->1200 to 3200 mg/day PO in 3-4 divided doses
-Dyspepsia-Heartburn-Increase BP-GI bleeding
-NSAIDS have BBW of increased risk of adverse CV thrombotic events; contraindicated for CABG perioperative pain; increased GI adverse events (ulceration, bleeding, perforation)-Contraindicated in pregnancy 3rd trimester.
-Avoid use in advanced renal disease
Naproxen(Aleve)
->250-500mg PO BID
-Edema-Abdominal pain-Tinnitus -Dyspnea
--NSAIDS have BBW of increased risk of adverse CV thrombotic events; contraindicated for CABG perioperative pain; increased GI adverse events (ulceration, bleeding, perforation)
-Max 1500mg/day for up to 6 mo
Celecoxib (Celebrex)
->100mg BID or 200mg daily
-Diarrhea-Nausea
-Warnings are the same as NSAIDS.-Contraindicated with sulfa allergy.
-Max 200mg
Pharmacological TreatmentTopical NSAIDS (preferred over oral NSAIDs for pts >75 yoa)
Topical Analgesics
Drug Dosage Adverse Effects
Warnings/ Contraindications
Notes
Diclofenac sodium 1% gel (Voltaren)
->4g topically to lower extremities 4x/day->2g to upper extremities 4x/day
-Application site rxn-Burning sens. in eye-Raised IOP
-Same as NSAIDs BBWs-NSAID oral therapy not recommended concomitantly -Can cause anaphylaxis
-Max 8g/day to any single joint of upper extremity; 16g/day for lower extremity; 32g/day total over all affected joints
Trolamine salicylate 10% cream (Arthricream)
->Apply topically 3-4x/day
-Erythema-Skin irritation
-Contraindications: hypersensitivity to salicylates, severe renal insufficiency
-May cause tinnitus-Beware of toxicity with over use-Do not cover area with occlusive material
Drug Dosage Adverse Effects Warnings/ Contraindications
Notes
Capsaisin 0.025% or 0.075%
->Apply to affected joints 3-4x/day
-Application site erythema-Pruritus-Nausea-Hypertension
-May increase risk of cardiovascular adverse effects
-Use nitrile gloves for handling
Pharmacological TreatmentIntra-acrticular Glucocorticoids (knee or hip)
Drug Dosage Adverse Effects
Warnings/ Contraindications
Notes
Triamcinolone acetonide (Kenalog, Aristocrat A, Nasacort)
->initial 2.5-15mg as single injection->Additional doses can be adjusted to 20mg or more
-Cushing’s syndrome-Headache-Pharyngitis-Flu-like symptoms
-Contraindications: administration with live vaccines; idiopathic thrombocytopenic purpura
-Increased risk of infections-Impaired skin healing-Weight gain-Hyperglycemia
Triamcinolone hexacetonide (Aristospan)
->up to 0.5mg/square inch of affected skin
-Hypertension-Osteoporosis
-Same as above -Same as above-Total daily dose may vary from 2-48mg/day
Pharmacist Role
Be aware of certain labs to order for particular agents
Understand patient populations, which certain medications should be avoided in
Counsel patients on the disease state , SE, possible treatments
Assess progression of disease and appropriate measures to take
Make recommendations to physicians regarding drug regimen
Clinical Pearls- Based on Guidelines
RA Etanercept recommended
for use in patients with hepatitis C.
No biologics for hepatitis B Rituxibam recommended
for pts with malignancy <5yrs, treated skin melanoma, treated lymphoproliferative disease
TNF inhibitor recommended for patients with CHF
OA Knee
Acetaminophen Oral NSAIDs Topical NSAIDs Tramadol Intraarticular corticosteroid
injections Hip
Same as above without topical NSAIDs
Hand Topical NSAIDs Topical capsaicin Oral NSAIDs
Reference American College of Rheumatology 2012 Recommendations for the
Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. American College of Rheumatology. vol. 64, No. 4, April 2012, pp 465–474
2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid ArthritisAmerican College of Rheumatology. vol. 64, No. 5, May 2012, pp 625–639
Kenneth C Kalunian, MD. Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics). UpToDate August 2013.
Peter H. Schur, MD. General principles of management of rheumatoid arthritis in adults. UpToDate August 2013
Micromedex